Mukosha Moses, Lubeya Mwansa Ketty, Mutale Wilbroad, Maposa Innocent, Chi Benjamin H, Hatcher Abigail
Department of Pharmacy, School of Health Sciences, University of Zambia, P.O. Box 32379, Lusaka, Zambia.
Faculty of Health Sciences, School of Public Health, University of the Witwatersrand, Johannesburg, South Africa.
Matern Child Health J. 2025 May 2. doi: 10.1007/s10995-025-04097-4.
Women recovering from preeclampsia with elevated vascular biomarkers have a higher risk of future cardiovascular diseases. We investigated whether HIV on treatment was associated with biomarkers of cardiovascular risk in the weeks following delivery.
We analyzed data from a six-month prospective cohort study conducted from January 2022 to June 2023. Following delivery and at six weeks postpartum, we measured cystatin C, high sensitivity C-reactive protein (hs-CRP), Interleukine-2 (IL-2), Interleukine-6 (IL-6) and Tumor necrosis factor-alpha (TNFa). A generalized linear regression model with Poisson distribution estimated the association between vascular biomarkers and HIV on treatment.
This study included 75 participants with a median age of 29 years (interquartile range [IQR] = 27-34 years), with 35 (46.7%) living with HIV on ART and 40 (53.3%) HIV-negative. Women living with HIV on ART had higher levels of hs-CRP than HIV-negative women (4.68 mg/l vs 3.60 mg/l, p = 0.025) at six weeks. On the other hand, women living with or without HIV on ART had similar levels of cystatin C (0.78 mg/l vs 0.81 mg/l, p = 0.303), IL-2 (0.64 pg/ml vs 0.67 pg/ml, p = 0.131), IL-6 (0.64 pg/ml vs 0.64 pg/ml, p = 0.422), and TNFa (24.2 pg/ml vs 24.1 pg/ml, p = 0.346). Living with HIV while on ART was associated with an increased risk of presenting as hypertensive with elevated hs-CRP (aRR = 2.88, 95% CI: 1.09-7.60).
Women living with HIV on ART had elevated hs-CRP but similar levels of other biomarkers after preeclampsia. Further studies are needed to explore the differential impact of HIV disease vs. antiretroviral treatment on inflammatory responses.
子痫前期康复且血管生物标志物升高的女性未来患心血管疾病的风险更高。我们调查了分娩后数周接受抗逆转录病毒治疗的艾滋病毒感染者是否与心血管疾病风险生物标志物有关。
我们分析了2022年1月至2023年6月进行的一项为期6个月的前瞻性队列研究的数据。分娩后及产后6周，我们测量了胱抑素C、高敏C反应蛋白（hs-CRP）、白细胞介素-2（IL-2）、白细胞介素-6（IL-6）和肿瘤坏死因子-α（TNFα）。采用泊松分布的广义线性回归模型估计血管生物标志物与接受抗逆转录病毒治疗的艾滋病毒之间的关联。
本研究纳入75名参与者，中位年龄为29岁（四分位间距[IQR]=27-34岁），其中35名（46.7%）接受抗逆转录病毒治疗的艾滋病毒感染者和40名（53.3%）艾滋病毒阴性者。产后6周，接受抗逆转录病毒治疗的艾滋病毒感染者的hs-CRP水平高于艾滋病毒阴性女性（4.68mg/l对3.60mg/l，p=0.025）。另一方面，接受或未接受抗逆转录病毒治疗的艾滋病毒感染者的胱抑素C水平（0.78mg/l对0.81mg/l，p=0.303）、IL-2水平（0.64pg/ml对0.67pg/ml，p=0.131）、IL-6水平（0.64pg/ml对0.64pg/ml，p=0.422）和TNFα水平（24.2pg/ml对24.1pg/ml，p=0.346）相似。接受抗逆转录病毒治疗的艾滋病毒感染者出现hs-CRP升高的高血压风险增加（调整后风险比[aRR]=2.88，95%置信区间：1.09-7.60）。
子痫前期后，接受抗逆转录病毒治疗的艾滋病毒感染者hs-CRP升高，但其他生物标志物水平相似。需要进一步研究以探讨艾滋病毒疾病与抗逆转录病毒治疗对炎症反应的不同影响。
